Nicholas Andrew Geisse
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2017First federal award
$9.2MFederal grants as PI22 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
22 awards · $9.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Nov 13, 2024 | NIH | SBIR Phase II A cross-species preclinical platform to enhance the translation of new medicines | $1.1M | CURI BIO, INC. |
| Nov 8, 2023 | NIH | SBIR Phase II A cross-species preclinical platform to enhance the translation of new medicines | $832K | CURI BIO, INC. |
| May 31, 2023 | NIH | SBIR Phase II A cross-species preclinical platform to enhance the translation of new medicines | $325K | CURI BIO, INC. |
| Nov 15, 2022 | NIH | SBIR Phase II Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs | $169K | CURI BIO, INC. |
| Aug 31, 2022 | NIH | SBIR Phase II Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs | $242K | CURI BIO, INC. |
| Aug 30, 2022 | NIH | SBIR Phase II Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs | $750K | CURI BIO, INC. |
| Mar 6, 2022 | NIH | SBIR Phase II Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs | $123K | CURI BIO, INC. |
| Sep 2, 2021 | NIH | SBIR Phase II Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs | $750K | CURI BIO, INC. |
| Jul 28, 2021 | NIH | SBIR Phase II Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing | $179K | CURI BIO, INC. |
| Jul 27, 2021 | NIH | SBIR Phase II Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing | $745K | CURI BIO, INC. |
| Mar 19, 2021 | NIH | SBIR Phase II Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing | $69K | CURI BIO, INC. |
| Jul 27, 2020 | NIH | SBIR Phase II Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs | $225K | CURI BIO, INC. |
| Jun 5, 2020 | NIH | SBIR Phase II Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing | $750K | CURI BIO, INC. |
| Sep 14, 2019 | NIH | SBIR Phase I Multiplexed quantitative measurements of field potential and contractility on biomimetically-matured hPSC-CMs | $225K | CURI BIO, INC. |
| Sep 13, 2019 | NIH | SBIR Phase I Low-cost, Roll-to-Roll Manufacturing of Nanoscale Biomimetic Scaffolds for Enhanced Biological Cell Culture | $222K | CURI BIO, INC. |
| Aug 16, 2019 | NIH | SBIR Phase II Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing | $225K | CURI BIO, INC. |
| Jul 24, 2019 | NIH | SBIR Phase II High-throughput nanoMEA-based Proarrhythmia Assay | $129K | CURI BIO, INC. |
| Jul 22, 2019 | NIH | SBIR Phase II High-throughput nanoMEA-based Proarrhythmia Assay | $124K | CURI BIO, INC. |
| Jul 11, 2019 | NIH | SBIR Phase II High-throughput nanoMEA-based Proarrhythmia Assay | $748K | CURI BIO, INC. |
| May 17, 2019 | NIH | SBIR Phase I A Combinatorial Bioreactor for Electromechanical Conditioning of Differentiated Stem Cells | $225K | CURI BIO, INC. |
| Sep 21, 2018 | NIH | SBIR Phase II High-throughput nanoMEA-based Proarrhythmia Assay | $748K | CURI BIO, INC. |
| Sep 21, 2017 | NIH | SBIR Phase I A Nanopatterned Interdigitated Electrode Array Device for Anti-migratory Cancer Drug Screening | $225K | CURI BIO, INC. |
Peer ranks
Federal funding#88
Awards as PI#15
Patents#505
Companies
- CURI BIO, INC.Linked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.